文献速递外周血管技术与安全CTPET

观察性队列研究显示银屑病患者的内脏脂肪堆积与18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描所见的血管炎症相关,且独立于心血管代谢疾病危险因素

Visceral Adiposity in Psoriasis is Associated With Vascular Inflammation by 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Beyond Cardiometabolic Disease Risk Factors in an Observational Cohort Study.
PubMed 文献 · JACC Cardiovasc Imaging · 2017-10-18

本研究为观察性队列,纳入77例连续性银屑病患者,用18F-FDG PET/CT测量血管炎症和腹部脂肪。内脏脂肪(β=0.55,p<0.001)而非皮下脂肪(β=0.15,p=0.11)在心血管危险因素之外与血管炎症相关。13例重症患者治疗后1年银屑病严重程度和内脏脂肪改善,且与血管炎症改善相关(β=0.53,p=0.049)。

要点

  • 银屑病患者内脏脂肪(VAT)在心血管危险因素之外与18F-FDG PET/CT血管炎症独立相关(β=0.55,p<0.001),皮下脂肪(SAT)无此关联(β=0.15,p=0.11)。
  • 银屑病严重程度与VAT相关(β=0.33,p=0.004),且独立于SAT(β=0.30,p=0.005)。
  • 重症银屑病患者治疗后1年VAT和血管炎症均改善,VAT改善在心血管危险因素之外与血管炎症改善相关(β=0.53,p=0.049)。

核心结论

  • 基于容积的CT测量VAT在银屑病患者中可能反映与血管炎症相关的代谢风险,优于皮下脂肪;银屑病治疗与VAT下降及血管炎症下降相关,提示VAT可能是与银屑病血管炎症相关的生物标志物。

研究设计与样本

  • 观察性队列研究,连续纳入77例银屑病患者行18F-FDG PET/CT测量血管炎症和腹部脂肪;其中13例重症皮肤病患者在银屑病治疗后1年复查。

关键影像表现/征象

  • 银屑病患者中,VAT在心血管危险因素之外与18F-FDG PET/CT血管炎症相关(β=0.55,p<0.001),SAT与血管炎症无显著关联(β=0.15,p=0.11)。
  • 银屑病疾病严重程度与VAT相关(β=0.33,p=0.004),且独立于SAT(β=0.30,p=0.005)。
  • 13例重症银屑病患者经积极治疗后随访1年,银屑病严重程度和VAT改善,且VAT改善在心血管危险因素之外与血管炎症改善相关(β=0.53,p=0.049)。

临床应用与阅片要点

  • 基于容积的CT测量VAT可用于评估银屑病患者与血管炎症相关的代谢风险,阅片时可关注腹部内脏脂肪的定量测量,而皮下脂肪与血管炎症无显著关联。

局限性

  • 原文报告了13例重症患者治疗前后1年的随访子集,样本量较小。
  • 原文结论提出VAT作为与银屑病血管炎症相关的生物标志物,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The authors sought to examine the relationship between visceral adipose tissue (VAT) and vascular inflammation (VI) by 18F-Fluorodeoxyglucose (18F-FDG) positron-emission tomography (PET)/computed tomography (CT) in psoriasis (PSO). Furthermore, we evaluated whether treatment of PSO modulated VAT and VI.

BACKGROUND: PSO, a chronic inflammatory skin disease, is associated with VI by 18F-FDG PET/CT and increased cardiometabolic risk including adipose tissue dysregulation. Recently, VI was associated with future cardiovascular events; however, the relationship of visceral and subcutaneous adiposity with VI in PSO has yet to be evaluated.

METHODS: Consecutive PSO patients (N = 77) underwent 18F-FDG PET/CT scans to measure VI and abdominal adiposity. A subset of PSO patients with severe skin disease was scanned at 1 year following PSO treatment (N = 13).

RESULTS: The cohort was middle aged (51.8 ± 12.6 years), predominantly male (n = 44, 57%), had low cardiovascular risk by Framingham 10-year risk (median 4 years [interquartile range (IQR): 2 to 7 years]), and mild-to-moderate skin disease (5.2 [IQR: 3.0 to 8.5]). PSO disease severity associated with VAT (β = 0.33; p = 0.004) beyond SAT (β = 0.30; p = 0.005). VAT (β = 0.55; p < 0.001), but not SAT (β = 0.15; p = 0.11), associated with VI beyond cardiovascular risk factors. We followed a subset of severe PSO patients treated aggressively for PSO and observed improvement in PSO severity and VAT, which was associated with an improvement in VI at 1 year beyond cardiovascular risk factors (β = 0.53; p = 0.049).

CONCLUSIONS: Volume-based CT measurement of VAT may capture metabolic risk associated with VI compared to subcutaneous adipose tissue in PSO. PSO treatment associated with a decrease in VAT as well as decrease in VI suggesting VAT as a relevant biomarker related to VI in PSO.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Rivers JP, Powell-Wiley TM, Dey AK, et al. Visceral Adiposity in Psoriasis is Associated With Vascular Inflammation by 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Beyond Cardiometabolic Disease Risk Factors in an Observational Cohort Study. JACC Cardiovasc Imaging. 2017. PMID: 29055628. doi:10.1016/j.jcmg.2017.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。